James R Gnarra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5443886/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Integrin αvβ3 and Fibronectin Upregulate Slug in Cancer Cells to Promote Clot Invasion and Metastasis. Cancer Research, 2013, 73, 6175-6184.	0.9	91
2	Association of the von Hippel–Lindau Protein with AUF1 and Posttranscriptional Regulation of VEGFA mRNA. Molecular Cancer Research, 2012, 10, 108-120.	3.4	27
3	Hypoxia and cell cycle regulation of the von Hippel–Lindau tumor suppressor. Oncogene, 2011, 30, 21-31.	5.9	27
4	EAF2 loss enhances angiogenic effects of Von Hippel-Lindau heterozygosity on the murine liver and prostate. Angiogenesis, 2011, 14, 331-343.	7.2	21
5	Cenotype–phenotype correlations of pheochromocytoma in two large von Hippel–Lindau (VHL) type 2A kindreds with different missense mutations. American Journal of Medical Genetics, Part A, 2011, 155, 168-173.	1.2	18
6	Lung Cancer Susceptibility in Fhit-Deficient Mice Is Increased by Vhl Haploinsufficiency. Cancer Research, 2005, 65, 6576-6582.	0.9	29
7	Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell, 2003, 3, 75-88.	16.8	143
8	Susceptibility to vascular neoplasms but no increased susceptibility to renal carcinogenesis in Vhl knockout mice. Carcinogenesis, 2003, 25, 309-315.	2.8	46
9	A Recombinant Adenovirus Expressing P27(KIP1) Induces Cell Cycle Arrest and Apoptosis In Human 786–O Renal Carcinoma Cells. Journal of Urology, 2002, 168, 766-773.	0.4	28
10	Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27Kip1. Prostate, 2002, 53, 77-87.	2.3	54
11	CLINICAL AND GENETIC CHARACTERIZATION OF PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU FAMILIES: COMPARISON WITH SPORADIC PHEOCHROMOCYTOMA GIVES INSIGHT INTO NATURAL HISTORY OF PHEOCHROMOCYTOMA. Journal of Urology, 1999, 162, 659-664.	0.4	233
12	The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells. Molecular and Cellular Biology, 1999, 19, 5902-5912.	2.3	194
13	von Hippel-Lindau Gene Mutations in Human and Rodent Renal TumorsAssociation With Clear Cell Phenotype. Journal of the National Cancer Institute, 1998, 90, 1685-1687.	6.3	14
14	Identification of an Actin Binding Region and a Protein Kinase C Phosphorylation Site on Human Fascin. Journal of Biological Chemistry, 1997, 272, 2527-2533.	3.4	166
15	Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proceedings of the United States of America, 1997, 94, 9102-9107.	7.1	319
16	Progelatinase A mRNA Expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival. Urology, 1997, 50, 295-301.	1.0	23
17	Von Hippel-Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens. Human Pathology, 1996, 27, 152-156.	2.0	41
18	Chromosome imbalances in papillary renal cell carcinoma and first cytogenetic data of familial cases analyzed by comparative genomic hybridization. Cytogenetic and Genome Research, 1996, 75, 17-21.	1.1	44

JAMES R GNARRA

#	Article	IF	CITATIONS
19	Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 10589-10594.	7.1	497
20	Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 1770-1775.	7.1	137
21	Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 1996, 1242, 201-210.	7.4	77
22	Comparative genomic analysis of tumors: detection of DNA losses and amplification Proceedings of the United States of America, 1995, 92, 151-155.	7.1	123
23	Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 6459-6463.	7.1	144
24	Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Human Mutation, 1995, 5, 66-75.	2.5	526
25	Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von hippel-lindau disease-associated, and familial pheochromocytoma. Genes Chromosomes and Cancer, 1995, 13, 151-156.	2.8	48
26	Renal cell carcinoma. Cancer Genetics and Cytogenetics, 1995, 82, 128-139.	1.0	37
27	Expression of NM23 in Cell Lines Derived from Patients with Metastatic Renal Cell Carcinoma. Journal of Urology, 1995, 154, 278-282.	0.4	10
28	Loss of Heterozygosity Occurs Centromeric to RB Without Associated Abnormalities in the Retinoblastoma Gene in Tumors from Patients with Metastatic Renal Cell Carcinoma. Journal of Urology, 1995, 153, 2050-2054.	0.4	17
29	cDNA Cloning and Expression of the Human Homolog of the Sea Urchin <i>fascin</i> and <i>Drosophila singed</i> Genes Which Encodes an Actin-Bundling Protein. DNA and Cell Biology, 1994, 13, 821-827.	1.9	75
30	The use of molecular genetic analysis in the diagnosis of renal cell carcinoma. World Journal of Urology, 1994, 12, 69-73.	2.2	5
31	Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors. Genes Chromosomes and Cancer, 1994, 11, 15-20.	2.8	32
32	Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genetics, 1994, 7, 85-90.	21.4	1,612
33	Loss of heterozygosity of the human cytosolic glutathione peroxidase I gene in lung cancer. Carcinogenesis, 1994, 15, 2769-2773.	2.8	122
34	Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 9700-9704.	7.1	1,382
35	Effect of suramin on the mitogenic response of the human prostate carcinoma cell line PC-3. Cancer, 1993, 71, 1151-1158.	4.1	11
36	Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene. Science, 1993, 260, 1317-1320.	12.6	2,723

JAMES R GNARRA

#	Δρτιςι ε	IF	CITATIONS
TT			CHAHONS
37	Interleukin (IL)-2 and IL-3 induce distinct but overlapping responses in murine IL-3-dependent 32D cells transduced with human IL-2 receptor beta chain: involvement of tyrosine kinase(s) other than p56lck Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 2789-2793.	7.1	58
38	Human interleukin 2 receptor beta-chain gene: chromosomal localization and identification of 5' regulatory sequences Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 3440-3444.	7.1	59
39	A 100-kilodalton protein is associated with the murine interleukin 2 receptor: biochemical evidence that p100 is distinct from the alpha and beta chains Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 4869-4873.	7.1	47
40	The Multisubunit Interleukin-2 Receptor. Annals of the New York Academy of Sciences, 1990, 594, 200-206.	3.8	8
41	Early Events in Target-Cell Lysis by Cytotoxic T Cells. Annals of the New York Academy of Sciences, 1988, 532, 303-313.	3.8	5
42	Increased intracellular cyclic adenosine monophosphate inhibits T lymphocyte-mediated cytolysis by two distinct mechanisms Journal of Experimental Medicine, 1988, 167, 1963-1968.	8.5	33
43	The role of K+ in the regulation of the increase in intracellular Ca2+ mediated by the T lymphocyte antigen receptor. Cell, 1987, 50, 119-127.	28.9	49